CClinicalTrials.gg
Enrolling by invitationNCT02791854IBD:QORUSUpdated Aug 21, 2025

Improving the Quality of Care for Adults With Inflammatory Bowel Disease

An observational study in Crohn's Disease, Ulcerative Colitis and Inflammatory Bowel Diseases, sponsored by Dartmouth-Hitchcock Medical Center. Enrolling by invitation at 29 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by Dartmouth-Hitchcock Medical Center · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years to 99 Years
Sex
All
01

Study summary

Innovative programs exist that suggest that care for people with chronic conditions is optimized when patients and providers have the information they need at the point of care and over time, to engage in shared planning and execution of treatment goals and care plans. This project aims to build an Inflammatory Bowel Disease Learning Health System, a shared information environment, that highlights collaboration among patients, clinicians and care team members, and researchers; for effective use of data for guiding care, value, improvement, and research.

Read the detailed description

To demonstrate the impact of an Adult Inflammatory Bowel Disease (IBD) Learning Health System approach the study collaborators will design, build, implement, and evaluate in up to 90 IBD care sites the the following four key components of the IBD Learning Health System: 1) a Health Information Technology (HIT) environment that can "feed-forward" Patient Reported Outcomes (PROs) and clinical data to be used at the point of care and integrated into a registry (IBD Plexus); 2) decision-support dashboards for use by patients and clinicians in real time to coproduce care; 3) meaningful reports for patients and clinicians; and 4) multi-stakeholder collaborative networks for improvement and research.

Prior work from Sweden and the US show that successful uptake of the model can offer important benefits. Patients will be able to use web-based tools to monitor their health and manage their care, securely share data with clinicians in a timely manner, visualize outcomes that matter to them, and compare their results to other people. Clinicians will have new information that can improve their ability to track patient outcomes and costs over time; use PRO data to support pre-visit planning, shared decision-making at the point of care, and post-visit monitoring; and receive comparative performance reports to support quality improvement, public reporting, and professional development. Researchers will benefit by having PROs and cost data added to data registries to support clinical, translational, and comparative effectiveness research.

02

Conditions studied

  • Crohn's Disease
  • Ulcerative Colitis
  • Inflammatory Bowel Diseases
03

In context

Crohn Disease

1,880 studies on the registry are indexed under Crohn Disease; 462 are open to participants now.

This study's planned enrollment of 10,000 is above the median of 162 across 608 observational studies indexed under Crohn Disease.

Browse Crohn Disease studies →

Lead sponsor

Dartmouth-Hitchcock Medical Center is the lead sponsor of 472 studies on the registry; 68 are open to participants now.

Of its 30 completed or terminated interventional studies of FDA-regulated products, 20 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

In order to participate in IBD Qorus, individuals must meet the following criteria:

  • 18 years of age or older
  • Diagnosis of Crohn's disease or ulcerative colitis or IBD unclassified
  • Accept the terms and conditions of Informed Consent and Authorization
  • Affiliated with a participating IBD Qorus site

Inclusion criteria

  • 18 years of age or older
  • Diagnosis of Crohn's disease or ulcerative colitis or IBD unclassified
  • Accept the terms and conditions of Informed Consent and Authorization
  • Affiliated with a participating IBD Qorus site

Exclusion criteria

Exclusion Criteria:

  • Inability to provide informed consent
  • Study key personnel cannot enroll as a study participant
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Target follow-up
20 Years
Patient registry
Yes

Groups and cohorts

  • Registry participant

    This is a registry study, the same information is collected from all participants.

06

What researchers measure

Primary outcomes

  1. Number of patients enrolled

    count of number of patients consented

    Time frame: annually, up to 5 years

Secondary outcomes

  1. Proportion of patients in remission

    assessed using a validated disease activity scale

    Time frame: annually, up to 5 years

  2. Proportion of patients on steroids

    assessed by patient report

    Time frame: annually, up to 5 years

  3. Proportion of patients admitted into the Emergency Room

    assessed by patient report

    Time frame: annually, up to 5 years

  4. Proportion of patients hospitalized

    assessed by patient report

    Time frame: annually, up to 5 years

  5. Proportion of patients with anemia

    assessed by patient report and labs

    Time frame: annually, up to 5 years

  6. Proportion of patients with malnutrition

    assessed by patient report and labs

    Time frame: annually, up to 5 years

07

Study locations

29 sites
  • Cedars-Sinai Inflammatory Bowel Disease Center
    Los Angeles, California 90048, United States
  • Hoag Digestive Health
    Newport Beach, California 92658, United States
  • UC San Diego Health Inflammatory Bowel Disease Center
    San Diego, California 92037, United States
  • University of Colorado Health
    Denver, Colorado 80045, United States
  • Yale School of Medicine IBD Program
    New Haven, Connecticut 06520, United States
  • MedStar Georgetown University Hospital Center for Inflammatory Bowel Disease
    Washington D.C., District of Columbia 20007, United States
  • Gastro Health LLC
    Miami, Florida 33133, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30342, United States
  • Digestive Health Center
    Boise, Idaho 83704, United States
  • University of Chicago Medicine Inflammatory Bowel Disease Center
    Chicago, Illinois 60637, United States
  • Digestive Care Center
    Evansville, Indiana 47714, United States
  • GastroIntestinal Specialists, A.M.C.
    Shreveport, Louisiana 71115, United States
  • Corewell Health
    Grand Rapids, Michigan 49546, United States
  • Dartmouth-Hitchcock Inflammatory Bowel Disease Center
    Lebanon, New Hampshire 03756, United States
  • Saratoga Schenectady Gastroenterology Associates
    Burnt Hills, New York 12027, United States
  • NYU Long Island- Inflammatory Bowel Disease Center
    Mineola, New York 11501, United States
  • New York University Langone Medical Center
    New York, New York 10016, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • The Oregon Clinic - Gastroenterology
    Portland, Oregon 97220, United States
  • Penn State Hershey Inflammatory Bowel Disease Center
    Hershey, Pennsylvania 17033, United States
  • Regional GI
    Lancaster, Pennsylvania 17601, United States
  • Gastroenterology Associates
    Providence, Rhode Island 02904, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Baylor College of Medicine IBD Center
    Houston, Texas 77030, United States
  • University of Utah Health Care
    Salt Lake City, Utah 84132, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02791854
Lead sponsor
Dartmouth-Hitchcock Medical Center
Collaborators
Crohn's and Colitis Foundation, Cedars-Sinai Medical Center, Dartmouth College
Responsible party
Corey Siegel (Section Chief, Section of Gastroenterology, Dartmouth-Hitchcock Medical Center) — Principal investigator
First posted
Jun 7, 2016
Start date
Feb 26, 2016
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Aug 21, 2025

Study contacts

Corey Siegel, MD, MS
principal investigator · Dartmouth-Hitchcock Medical Center
Gil Melmed, MD, MS
principal investigator · Cedars-Sinai Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion